Anti-Obesity Drug Discovery and Development
Journal formatting to fit the target journal guidelines
Experts ensure all elements of your paper match journal formatting guidelines to improve publication success rate!
Key Metrics
Journal Specifications
- PublisherBentham
Ready to spotlight your research findings?
Impress peers and journals alike with a concise, visual summary of your work.
Meets Top Publisher Standards: Essential for leading journals like Elsevier.Enhances Engagement: Research papers with graphical abstracts receive 3X more downloads and 8X more shares.Tailored Just for You: We’ll create a custom graphical abstract based on your manuscript—no sketches needed.
3000+ graphical abstracts produced with 4.8/5 customer rating FAQs
Who is the publisher of Anti-Obesity Drug Discovery and Development? 
The publisher of Anti-Obesity Drug Discovery and Development is Bentham.
How can I view the journal metrics of Anti-Obesity Drug Discovery and Development on editage?
For the Anti-Obesity Drug Discovery and Development metrics, please refer to the section above on the page.
What is the eISSN and pISSN number of Anti-Obesity Drug Discovery and Development?
The eISSN number is 2210-2698 and pISSN number is 2467-9615 for Anti-Obesity Drug Discovery and Development.
Why is it important to find the right journal for my research?
Choosing the right journal ensures that your research reaches the most relevant audience, thereby maximizing its scholarly impact and contribution to the field.
Can the choice of journal affect my academic career?
Absolutely. Publishing in reputable journals can enhance your academic profile, making you more competitive for grants, tenure, and other professional opportunities.
Is it advisable to target high-impact journals only?
While high-impact journals offer greater visibility, they are often highly competitive. It's essential to balance the journal's impact factor with the likelihood of your work being accepted.